Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

BACKGROUND: We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with an encouraging rate of pathologic response. Building on these results, and promising data for nivolumab plus ipilimumab (...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Main Authors: Reuss, Joshua E, Anagnostou, Valsamo, Cottrell, Tricia R, Smith, Kellie N, Verde, Franco, Zahurak, Marianna, Lanis, Mara, Murray, Joseph C, Chan, Hok Yee, McCarthy, Caroline, Wang, Daphne, White, James R, Yang, Stephen, Battafarano, Richard, Broderick, Stephen, Bush, Errol, Brock, Malcolm, Ha, Jinny, Jones, David, Merghoub, Taha, Taube, Janis, Velculescu, Victor E, Rosner, Gary, Illei, Peter, Pardoll, Drew M, Topalian, Suzanne, Naidoo, Jarushka, Levy, Ben, Hellmann, Matthew D, Brahmer, Julie R, Chaft, Jamie E, Forde, Patrick M
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2020
Teme:
Short Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7488786/
https://ncbi.nlm.nih.gov/pubmed/32929052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001282
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki